Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07457736 · ClinicalTrials.gov registry record · Early Phase 1

Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1

A Early Phase 1 study of Healthy Adult Participants, sponsored by Yale University.

Recruiting
Registry status
Early Phase 1
Development phase
32
Enrollment target
1
Study location

NCT07457736 is a Early Phase 1 study of Healthy Adult Participants that is actively recruiting participants, run by Yale University. The registered enrollment target is 32 participants, below the 72-participant average among 4 other Healthy Adult Participants trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07457736, a Early Phase 1 study of Healthy Adult Participants, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
Early Phase 1
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

Evaluate \[18F\]GATT-44 (aka \[18F\]GAT44), to characterize its pharmacokinetic, metabolic, and in vivo binding profile, and assess the reproducibility of kinetic and binding parameters. Assess specific binding levels of \[18F\]GATT-44 by conducting a test-block study in humans. Estimate human dosimetry of \[18F\]GATT-44 by performing whole-body imaging studies.

Conditions Studied

Interventions

  • DRUG [ 18F]GATT-44

Study Locations (1)

Connecticut

  • Yale University PET Center - New Haven

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2026-03
Est. Completion 2030-01
Phase Early Phase 1

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT07457736

The ClinicalTrials.gov registry entry for NCT07457736 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 72-participant average among 4 other Healthy Adult Participants trials with a reported enrollment target (56% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Adult Participants appearing as the primary indexed condition, and to 1 intervention - of which [ 18F]GATT-44 is the first listed.

NCT07457736 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT07457736 about?

NCT07457736 is a clinical study titled "Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1". Evaluate \[18F\]GATT-44 (aka \[18F\]GAT44), to characterize its pharmacokinetic, metabolic, and in vivo binding profile, and assess the reproducibility of kinetic and binding parameters. Assess specific binding levels of \[18F\]GATT-44 by conducting a test-block study in humans. Estimate human dosim...

What is the current status of trial NCT07457736?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 32 participants. The study started on 2026-03. Estimated completion is 2030-01.

What conditions does trial NCT07457736 study?

This clinical trial studies the following conditions: Healthy Adult Participants.

What interventions are being tested in trial NCT07457736?

The interventions under investigation include: [ 18F]GATT-44 (DRUG).

Who is sponsoring clinical trial NCT07457736?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07457736 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Adult Participants

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.